Puerto Rico’s biosciences sector, which accounts for about 28 percent of the island’s gross domestic product and generates more than 100,000 direct and indirect jobs, will look for ways to transform its future during its 10th annual “Biosciences Week” event this week.
CDI Laboratories in Mayagüez — the only company in the world using pioneering technology with the ability to generate high specificity monoclonal antibodies — began a new phase of research after receiving a combined $11.4 million in local and federal funding to develop new technologies in the field of medicine.
Puerto Rico is among a select group of U.S. jurisdictions specializing in four of the five sectors that make up the thriving bioscience industry and is among a handful of states boasting a significant employment base and a specialized concentration of jobs in drugs and pharmaceuticals, according to the findings of the “Battelle/BIO State Bioscience Industry Development Report” released Wednesday.
A Dow Jones/Factiva content provider since 2014
Subscribe to our Dollars & Sense podcast!
